MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer A G Ord (OP:BAYZF)

43.80 UNCHANGED
Streaming Delayed Price Updated: 11:22 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer A G Ord

< Previous 1 2 3 4 Next >
News headline image
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
News headline image
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial ↗
Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)  
Via Benzinga
News headline image
Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial ↗
Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's. 
Via Benzinga
News headline image
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak ↗
In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin... 
Via Benzinga
Topics Lawsuit
News headline image
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US ↗
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... 
Via Benzinga
Topics Climate Change
News headline image
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death ↗
 
Via Benzinga
News headline image
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug ↗
 
Via Benzinga
News headline image
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss ↗
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
News headline image
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion ↗
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts  
Via Benzinga
Topics Lawsuit
News headline image
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... 
Via Benzinga
News headline image
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence ↗
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
News headline image
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
News headline image
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits ↗
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
Via Benzinga
Topics Lawsuit
News headline image
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced  
Via Benzinga
News headline image
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
News headline image
From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
News headline image
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
News headline image
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
News headline image
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
News headline image
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities ↗
 
Via Benzinga
News headline image
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B ↗
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
News headline image
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm ↗
 
Via Benzinga
News headline image
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Activist Investor Builds Stake In Bayer, Pushes Breakup ↗
Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.  
Via Benzinga
News headline image
Ionis Regains Rights To Thrombosis Candidate From Bayer ↗
 
Via Benzinga
News headline image
Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor ↗
Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup... 
Via Benzinga
News headline image
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report ↗
 
Via Benzinga
News headline image
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story